Medtronic (NYSE:MDT) said today that the 1st procedure using the Visualase MRI-Guided laser ablation system has been performed in its SLATE clinical trial evaluating the device in patients with drug-resistant mesial temporal lobe epilepsy.
The trial is slated to enroll 120 patients with MTLE, the most common form of epilepsy. Researchers will observe the patients for 12 months following the procedure and evaluate them for freedom from seizures, quality of life, adverse events and neuropsychological outcomes.